IDH2 and acute myeloid leukemia: IDH inhibitors combined with other anticancer agents may be more effective in IDH-mutated AML than IDH inhibitors alone, but this requires better evaluation after completion of relevant ongoing and unstarted studies (e.g. NCT04774393, NCT04250051, NCT05441514).